Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

European AIDS Clinical Society (EACS) guidelines. Version 6.1-2, http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EacsGuidelines-v6.1-2edition.pdf (2012, accessed 11 March 2013).

Bierman

van Agtmael

Nijhuis

. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23: 279–291.

Mathis

Khanlari

Pulido

. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One 2011; 6: e22003–e22003.

Lambert-Niclot

Flandre

Valantin

. Factors associated with virological failure in HIV-1–infected patients receiving darunavir/ritonavir monotherapy. J Inf Dis 2011; 204: 1211–1216.

Pulido

Pérez-Valero

Delgado

. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antiviral Ther 2009; 14: 195–201.

Gutmann

Cusini

Gunthard

. Randomised, controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 2010; 24: 2347–2354.

Pulido

Hill

van Delft

. Impact of hepatitis C co-infection on response to antiretroviral treatment. AIDS Rev 2012; 14: 124–131.

Arribas

Clumeck

Hill

. The MONET Trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load <50 HIV-1 RNA copies/mL at baseline. HIV Med 2012; 13: 398–405.

Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial

Abstract

Get full access to this article

References